Steven Cohen's RARE Position Overview
Steven Cohen (via Point72 Asset Management, L.P.) currently holds 893,295 shares of Ultragenyx Pharmaceutical Inc. (RARE) worth $18.71 M, representing 0.02% of the portfolio. First purchased in 2017-Q1, this long-term strategic position has been held for 34 quarters.
Based on 13F filings, Steven Cohen has maintained a strategic position in RARE, demonstrating sustained confidence in this investment. Largest addition occurred in Q1 2026, adding 893,295 shares. Largest reduction occurred in Q2 2023, reducing 961,987 shares.
Analysis based on 13F filings available since 2013 Q2
Steven Cohen's Ultragenyx Pharmaceutical (RARE) Holding Value Over Time
Track share changes against reported price movement
Quarterly Ultragenyx Pharmaceutical (RARE) Trades by Steven Cohen
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q1 2026 | +893,295 | New Buy | 893,295 | $20.95 |
| Q3 2025 | -515,968 | Sold Out | 0 | $0.00 |
| Q2 2025 | -460,084 | Reduce 47.14% | 515,968 | $36.36 |
| Q1 2025 | -206,825 | Reduce 17.48% | 976,052 | $36.21 |
| Q4 2024 | +529,217 | Add 80.96% | 1.18 M | $42.07 |
| Q3 2024 | +113,911 | Add 21.10% | 653,660 | $55.55 |
| Q2 2024 | +478,849 | Add 786.29% | 539,749 | $41.10 |
| Q1 2024 | -41,600 | Reduce 40.59% | 60,900 | $46.69 |
| Q4 2023 | -613,962 | Reduce 85.69% | 102,500 | $47.82 |
| Q3 2023 | +291,588 | Add 68.63% | 716,462 | $35.65 |
| Q2 2023 | -961,987 | Reduce 69.36% | 424,874 | $46.13 |
| Q1 2023 | +659,174 | Add 90.58% | 1.39 M | $40.10 |
| Q4 2022 | +377,000 | Add 107.50% | 727,687 | $46.33 |
| Q3 2022 | +77,172 | Add 28.21% | 350,687 | $41.41 |
| Q2 2022 | -44,982 | Reduce 14.12% | 273,515 | $59.66 |
| Q1 2022 | -107,377 | Reduce 25.21% | 318,497 | $72.62 |
| Q4 2021 | +85,500 | Add 25.12% | 425,874 | $84.09 |
| Q3 2021 | -366,926 | Reduce 51.88% | 340,374 | $90.19 |
| Q2 2021 | +587,700 | Add 491.39% | 707,300 | $95.35 |
| Q1 2021 | -100 | Reduce 0.08% | 119,600 | $113.86 |
| Q4 2020 | +119,700 | New Buy | 119,700 | $138.43 |
| Q1 2020 | -117,496 | Sold Out | 0 | $0.00 |
| Q4 2019 | +61,680 | Add 110.51% | 117,496 | $42.71 |
| Q3 2019 | +21,553 | Add 62.90% | 55,816 | $42.78 |
| Q2 2019 | +34,263 | New Buy | 34,263 | $63.51 |
| Q1 2019 | -173,700 | Sold Out | 0 | $0.00 |
| Q4 2018 | +138,700 | Add 396.29% | 173,700 | $43.48 |
| Q3 2018 | -25,000 | Reduce 41.67% | 35,000 | $76.34 |
| Q2 2018 | -10,000 | Reduce 14.29% | 60,000 | $76.87 |
| Q1 2018 | -23,400 | Reduce 25.05% | 70,000 | $50.99 |
| Q4 2017 | +43,400 | Add 86.80% | 93,400 | $46.38 |
| Q3 2017 | -15,000 | Reduce 23.08% | 50,000 | $53.26 |
| Q2 2017 | -15,000 | Reduce 18.75% | 65,000 | $62.11 |
| Q1 2017 | +80,000 | New Buy | 80,000 | $67.78 |
Steven Cohen's Ultragenyx Pharmaceutical Investment FAQs
Steven Cohen first purchased Ultragenyx Pharmaceutical Inc. (RARE) in Q1 2017, acquiring 80,000 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Steven Cohen has held Ultragenyx Pharmaceutical Inc. (RARE) for 34 quarters since Q1 2017.
Steven Cohen's largest addition to Ultragenyx Pharmaceutical Inc. (RARE) was in Q1 2026, adding 893,295 shares worth $18.71 M.
According to the latest 13F filing for Q1 2026, Steven Cohen's firm, Point72 Asset Management, L.P., owns 893,295 shares of Ultragenyx Pharmaceutical Inc. (RARE), valued at approximately $18.71 M.
As of the Q1 2026 filing, Ultragenyx Pharmaceutical Inc. (RARE) represents approximately 0.02% of Steven Cohen's publicly disclosed stock portfolio, making it one of their key holdings.
Steven Cohen's peak holding in Ultragenyx Pharmaceutical Inc. (RARE) was 1,386,861 shares, as reported at the end of Q1 2023.